ReSurfX

How can a ZERO from an analytics product get a great ROI and improve innovation for your enterprise?

Recently we released a new version of our analytics product ReSurfX::vysen 2.0 – initially showcasing the power of our Adaptive Hypersurface Technology (AHT)™ using RNAseq and Microarray based gene expression analysis.

Here we prove the power of vysen using unprecedented results with enormous impact for analytics and outcomes. This forms one basis for  vysen being the most accurate product in the market.

We analyzed sequencing quality control consortium (SEQC) benchmark data from two sites (Mayo Clinic and Beijing Genomics Institute) that had each carried out sequencing (RNAseq) analysis on two different tissue samples with 5 replicates each. We found that ReSurfX::vysen :

• Identified ‘ZERO’ false positive differentially expressed gene from over 10 million calls IN 180 (EVERY within-sample 3-replicate) COMPARISONS  EACH INVOLVING 58,051 GENES, proving remarkable false positive control.

• Is incredibly MORE SENSITIVE AND REPRODUCIBLE THAN ANY OTHER APPROACH through direct comparison, as well as comparing ALL POSSIBLE between-sample THREE-REPLICATE COMBINATIONS. This involved 200 vysen comparisons of 58,051 genes in over 11 million DEG calls.

Read more...

A general validation outline covering several technologies and datasets can be found here.